Interestingly, the final differentiation of both T and B cells involves a BLIMP1-independent clonal-expansion phase, followed by the production of short-lived effector cells that require BLIMP1 to ...

针对剧烈变异的病原微生物，如何利用基因编辑实现可设计的抗病育种？近日，上海交通大学陆钰明教授课题组在国际权威期刊Cell Discovery在线发表了题为“Programmable broad-spectrum resistance to ...

eFFECTOR Therapeutics (NASDAQ:EFTR) just reported results for the fourth quarter of 2023. eFFECTOR Therapeutics reported earnings per share of -$3.42. This was below the analyst estimate for EPS of ...

eFFECTOR Therapeutics, Inc., a biopharmaceutical company, engages in the development of selective translation regulator inhibitors (STRIs) for the treatment of cancer. The company’s lead product ...

Study examined the effects of caloric restriction (CR) and intermittent fasting (IF) on the health and lifespan of ...

GITAI USA Inc. (GITAI), the world's leading space robotics startup, is pleased to announce that GITAI's Inchworm-type Robot ...

State Key Laboratory of Microbial Metabolism, Joint International Research Laboratory of Metabolic & Developmental Sciences, School of Life Sciences and Biotechnology, Shanghai Jiao Tong University, ...

In this podcast, Motley Fool analyst Jason Moser and host Mary Long discuss the semiconductor supply chain, ASML's earnings, ...

Calluna Pharma AS (Calluna), a clinical stage biotechnology company pioneering first-in-class antibodies to treat ...

This valuable study reports on a novel role of PD-1 in early T cell differentiation, showing that PD-1 stimulation impairs Th2 differentiation more effectively than that of Th1, with implications for ...

SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage medical device company developing proprietary solutions ...